Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Receives Average Recommendation of “Strong Buy” from Analysts

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) has received a consensus rating of “Strong Buy” from the five analysts that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company.

A number of analysts recently issued reports on CURLF shares. Zacks Research raised shares of Curaleaf from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Citigroup reiterated a “buy” rating on shares of Curaleaf in a research note on Thursday, August 6th.

More Curaleaf News

Here are the key news stories impacting Curaleaf this week:

• Positive Sentiment: Curaleaf proposed acquiring Aurora for approximately $272 million, offering 0.3463 Curaleaf shares plus $0.75 in cash for each Aurora share. The roughly $4-per-share proposal represents a reported 45% premium to Aurora’s 30-day VWAP and is designed to accelerate Curaleaf’s global expansion. Curaleaf takeover announcement
• Positive Sentiment: The combination would pair Aurora’s EU-GMP cultivation and manufacturing capacity—reported at about 50 metric tons annually—with Curaleaf’s international processing and distribution network. Management argues the deal could improve supply reliability, margins and patient access across Europe, Canada, Australia and New Zealand. Is Acquiring Aurora Cannabis a Good Move for Curaleaf?
• Positive Sentiment: Curaleaf’s ability to pursue the transaction is supported by recent U.S. tax relief tied to cannabis rescheduling. A reported $38.8 million tax benefit helped produce approximately $12.5 million of quarterly GAAP net income and could provide liquidity for the cash component of the bid. Analysts have also maintained an average “Strong Buy” rating on CURLF. Curaleaf analyst rating
• Neutral Sentiment: Aurora’s board has criticized aspects of the proposal but formed a special committee to evaluate it. The 105-day tender-offer process could lead to negotiations, rejection or a competing bid, making the deal’s timing and completion uncertain. Curaleaf hostile takeover bid investor analysis
• Negative Sentiment: The acquisition would require issuing Curaleaf shares and spending cash, potentially diluting existing CURLF shareholders and increasing integration risk. Aurora’s strong cash position and resistance to the bid could force Curaleaf to improve its offer, while the proposed consideration cap may limit the transaction’s upside. Curaleaf plans hostile bid for Aurora Cannabis

Curaleaf Price Performance

CURLF stock opened at $9.87 on Thursday. The stock has a 50-day moving average price of $6.93 and a two-hundred day moving average price of $7.75. Curaleaf has a 12-month low of $5.40 and a 12-month high of $15.15. The company has a current ratio of 1.52, a quick ratio of 0.73 and a debt-to-equity ratio of 1.06. The company has a market cap of $2.30 billion, a PE ratio of -75.91 and a beta of 1.56.

Curaleaf (OTCMKTS:CURLF) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.25. The company had revenue of $340.10 million for the quarter, compared to the consensus estimate of $332.00 million. Curaleaf had a negative return on equity of 0.88% and a negative net margin of 2.62%. As a group, research analysts predict that Curaleaf will post -0.05 EPS for the current year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.